Research programme: small molecule therapeutics - Hetero Labs/Sihuan Pharmaceutical
Alternative Names: Coronovirus (2019-nCoV) therapeuticsLatest Information Update: 28 Mar 2024
At a glance
- Originator Hetero Biopharma; Sihuan Pharmaceutical Holdings Group
- Class Anti-infectives; Antivirals; Cardiovascular therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported COVID 2019 infections; Vascular disorders
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for research development in COVID-2019-infections in China
- 28 Mar 2024 No recent reports of development identified for research development in COVID-2019-infections in India
- 28 Mar 2024 No recent reports of development identified for research development in Vascular-disorders in China
Development Overview
Introduction
Small molecule therapeutics are being developed by Hetero Labs and Sihuan Pharmaceutical for cardiovascular, cerebrovascular, neurological and infective indications including coronavirus strain (2019-nCoV, SARS-CoV-2). Early research is underway in China and India.
As at March 2024, no recent reports of development had been identified for research development in COVID-2019-infections in China, India, research development in Vascular-disorders in China, India.
Company Agreements
In February 2020, Sihuan Pharmaceutical and Hetero Labs entered into a framework co-operation agreement. According to the terms of the agreement Sihuan Pharmaceutical will introduce Hetero Biopharma's anti-virals and anti-infection products. The cooperation includes product registration, research and development, technology transfer, raw materials supply and local manufacturing and commercialization of drugs in the fields of cardiovascular, cerebrovascular, neurology and anti-infective agents that include coronavirus (2019-nCoV) [1]
Drug Properties & Chemical Synopsis
- Formulation unspecified
- Class Anti-infectives, Antivirals, Cardiovascular therapies, Small molecules
- Mechanism of Action Undefined mechanism
-
WHO ATC code
C (Cardiovascular System)
S01A-D (Antivirals)
-
EPhMRA code
C (Cardiovascular System)
J5B (Antivirals, excluding anti-HIV products)
Development Status
Summary Table
| Indication | Qualifier | Patient Segment | Phase | Countries | Route / Formulation | Developers | Event Date |
|---|---|---|---|---|---|---|---|
| COVID 2019 infections | - | - | No development reported (Research) | China, India | unspecified / unspecified | Hetero Biopharma, Sihuan Pharmaceutical Holdings Group | 28 Mar 2024 |
| Vascular disorders | cardiovascular and cerebrovascular diorders | - | No development reported (Research) | China, India | unspecified / unspecified | Hetero Biopharma, Sihuan Pharmaceutical Holdings Group | 28 Mar 2024 |
Commercial Information
Involved Organisations
| Organisation | Involvement | Countries |
|---|---|---|
| Hetero Biopharma | Originator | India |
| Sihuan Pharmaceutical Holdings Group | Originator | Hong-Kong |
| Sihuan Pharmaceutical Holdings Group | Owner | Hong-Kong |
| Hetero Biopharma | Owner | India |
Development History
| Event Date | Update Type | Comment |
|---|---|---|
| 28 Mar 2024 | Phase Change - No development reported | No recent reports of development identified for research development in COVID-2019-infections in China Updated 28 Mar 2024 |
| 28 Mar 2024 | Phase Change - No development reported | No recent reports of development identified for research development in COVID-2019-infections in India Updated 28 Mar 2024 |
| 28 Mar 2024 | Phase Change - No development reported | No recent reports of development identified for research development in Vascular-disorders in China Updated 28 Mar 2024 |
| 28 Mar 2024 | Phase Change - No development reported | No recent reports of development identified for research development in Vascular-disorders in India Updated 28 Mar 2024 |
| 21 Feb 2020 | Licensing Status | Hetero labs and Sihuan Pharmaceuticals agree to co-promote and co-develop coronavirus therapeutics in China and India for Coronavirus infection [1] Updated 02 Mar 2020 |
| 12 Feb 2020 | Phase Change | Early research in COVID-2019-infections in China (Unspecified) [1] Updated 02 Mar 2020 |
| 12 Feb 2020 | Phase Change | Early research in COVID-2019-infections in India (Unspecified) [1] Updated 02 Mar 2020 |
| 12 Feb 2020 | Phase Change | Early research in Vascular disorders in China (Unspecified) [1] Updated 02 Mar 2020 |
| 12 Feb 2020 | Phase Change | Early research in Vascular disorders in India (Unspecified) [1] Updated 02 Mar 2020 |
References
-
Sihuan Pharmaceutical and Hetero Labs Limited Reached A Framework Cooperation Agreement in Pharmaceutical Manufacturing Area.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG